September 26, 2019
Takeda presents efficacy for nacrolepsy type 1 Orexin receptor agonist TAK-925
Takeda’s presentation has shown TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo.
Pharmaceuticals, Biotechnology and Life Sciences
Takeda’s presentation has shown TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo.